NCT07337629 Single Dose Preemptive Paracetamol or Ibuprofen Before Septrorhinoplasty on Intra- and Postoperative Opioid Consumption.
| NCT ID | NCT07337629 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsun University |
| Condition | Analgesia |
| Study Type | OBSERVATIONAL |
| Enrollment | 54 participants |
| Start Date | 2025-11-24 |
| Primary Completion | 2026-11-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 54 participants in total. It began in 2025-11-24 with a primary completion date of 2026-11-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Reducing intra- and postoperative pain or using less opioids is an essential strategy in today's operations. One emerging and widely used method in this context is the use of preemptive analgesic medication. Paracetamol and ibuprofen used preemptively have been shown to reduce postoperative opioid use and pain scores. There are also studies showing that preemptive analgesia with different analgesic medications reduces opioid consumption and postoperative pain. Our study will evaluate both the intraoperative and postoperative effectiveness of paracetamol and ibupurofen with preemptive analgesia, considering total opioid use. It will also investigate drug side effects and their advantages using a 15-question compilation quality scale, validated in Turkish.
Eligibility Criteria
Inclusion Criteria: * Septorhinoplasty surgery * ASA1-2 patients * Men and women aged 18-65 * Informed consent and acceptance to participate in the study Exclusion Criteria: * ASA 3-4 and under 18 years of age * Patients with serious renal, hepatological, cardiovascular, or pulmonary system diseases * Allergy to paracetamol or ibuprofen * Patients with bleeding diathesis, platelet dysfunction, GI disease, peptic ulcers, pregnancy, planning pregnancy, and breastfeeding mothers * Patients using ASA or anticoagulants
Contact & Investigator
Hasan Cetinkaya, M.D.
PRINCIPAL INVESTIGATOR
Samsun University Samsun Educational and Research Hospital
Frequently Asked Questions
Who can join the NCT07337629 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07337629 currently recruiting?
Yes, NCT07337629 is actively recruiting participants. Contact the research team at drhasancetinkaya@gmail.com for enrollment information.
Where is the NCT07337629 trial being conducted?
This trial is being conducted at Samsun, Turkey (Türkiye).
Who is sponsoring the NCT07337629 clinical trial?
NCT07337629 is sponsored by Samsun University. The principal investigator is Hasan Cetinkaya, M.D. at Samsun University Samsun Educational and Research Hospital. The trial plans to enroll 54 participants.